Chengdu Sydix Biotech Co., Ltd (subsidiary of Guilin Layn Bio-Tech, SZSE:002166) pioneers synthetic biology innovation, producing Frucan®—a novel-structured biopolysaccharide via cell-factory technology. Established in 2000, its 500-acre GMP facility integrates automated extraction and sustainable systems. With ISO/cGMP certifications and GRAS status, Layn delivers plant-based sweeteners and functional polysaccharides for global food, cosmetics, and nutraceutical markets, serving 60+ countries including industry leaders.
CHENGDU BRANDNEW SIGN EXPRESS CO.,LTD
Chengdu Brandnew Sign Express Co., Ltd. is dedicated to sign system manufacturing, and is an integrated industry and trade enterprise with over 28 years of experience in sign system production. We specialize in providing “one-stop service solutions and maintenance solutions” for customers, from the planning and design of sign system projects, process evaluation, prototype production, mass production, quality inspection and delivery, to after-sales maintenance.
CAMY New Energy Co.,Ltd.
CAMY is mainly focused on providing customers in the GSE area with advanced LFP/semi solid-state battery/hydrogen-powered hybrid solutions. We can supply all kinds of battery cells, including block/cylindrical/blade types modularized to the final packs for customers’ specific needs on voltage and capacity. Our successful applications are on airplane tugs, towing tractors, loaders, forklifts, GPUs, etc. for the major players in GSE worldwide.
C Ray Therapeutics (Chengdu) Co., Ltd.
C Ray Therapeutics Group operates an R&D center in Shanghai, focused on proprietary pipeline development. This covers early discovery, process development, clinical research, and registration. The company has established over 10 development pipelines targeting solid tumors, utilizing isotopes such as Cu-64, Lu-177, and Ac-225, with a variety of ligands, including small molecules, peptides, and modified antibodies. Several pipelines feature globally innovative molecules with independent intellectual property rights. | C-Ray Therapeutics is dedicated to delivering end-to-end solutions for innovative radiopharmaceuticals to clients around the world. Our services span process development, quality research, preclinical evaluation, IND Enabling, clinical supply, and commercial scale cGMP production, all backed by a reliable, robust logistics network. As of 2024, we have raised over USD 187 million in total funding. C-Ray has 28,000 square-meter, state-of-the-art, world class R&D and cGMP manufacturing facilities with the highest Class A Radiation Safety License, allowing commercial scale operational volume of over 30+ radioisotopes. GLP-like preclinical study center has both small and large lab animal use permit with animal feeding and administration lab, animal PET/CT for imaging, gama counter and pathology lab for biodistribution and dosimetry analysis. C-Ray has successfully delivered and continues to operate 70 CRDMO projects, including 50 preclinical and molecular imaging CRO projects and 24 CDMO projects. Among these, 5 have entered the IND and IND-enabling stages, 16 have advanced to investigator-initiated trials (IITs), and 5 have entered the clinical supply stage, with 2 of them successfully progressing to a Phase III clinical study. The company has achieved comprehensive coverage of all critical links across the entire radiopharmaceutical R&D and manufacturing chain. As a dedicated CRDMO partner in radiopharmaceuticals, one of our core strengths is a stable, diversified supply of radionuclides. We are actively developing high-quality domestic sources while playing a leading role in integrating and fortifying the global supply chain—most notably securing access to challenging isotopes such as Ac-225. To date, we have supported the development of 19 Ac-225–labeled projects.
